| 261.23 0.42 (0.16%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 318.2 | 1-year : | 371.66 |
| Resists | First : | 272.44 | Second : | 318.2 |
| Pivot price | 258.87 |
|||
| Supports | First : | 252.78 | Second : | 240.63 |
| MAs | MA(5) : | 266.4 |
MA(20) : | 256.68  |
| MA(100) : | 245.14 |
MA(250) : | 227.17 |
|
| MACD | MACD : | 3.4 |
Signal : | 2.7 |
| %K %D | K(14,3) : | 65.6 |
D(3) : | 79.8 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 282.14 | Low : | 186.05 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ASND ] has closed below upper band by 48.2%. Bollinger Bands are 9.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 271.75 - 273.38 | 273.38 - 274.59 |
| Low: | 256.9 - 259.03 | 259.03 - 260.61 |
| Close: | 258.04 - 261.15 | 261.15 - 263.47 |
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Wed, 09 Sep 2026
Ascendis Pharma (ASND) officer cashes 3K warrants, sells matching shares - stocktitan.net
Wed, 09 Sep 2026
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors - ChartMill
Tue, 08 Sep 2026
H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $344 - Moomoo
Tue, 08 Sep 2026
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Tue, 08 Sep 2026
Ascendis Pharma (NASDAQ: ASND) officer lines up 3,000-ADS sale for 2026 - stocktitan.net
Tue, 08 Sep 2026
Ascendis Pharma A/S Trade Ideas — HAM:A710 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 103.2 (%) |
| Shares Short | 3,690 (K) |
| Shares Short P.Month | 3,100 (K) |
| EPS | 12.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25.4 |
| Profit Margin | 70.8 % |
| Operating Margin | 64.9 % |
| Return on Assets (ttm) | 9.5 % |
| Return on Equity (ttm) | 118.7 % |
| Qtrly Rev. Growth | 114.6 % |
| Gross Profit (p.s.) | 14.57 |
| Sales Per Share | 16 |
| EBITDA (p.s.) | 4.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 350 (M) |
| Levered Free Cash Flow | 13 (M) |
| PE Ratio | 20.01 |
| PEG Ratio | 0 |
| Price to Book value | 10.2 |
| Price to Sales | 16.2 |
| Price to Cash Flow | 48.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|